Deutsche Bank’s NewAmsterdam Pharma NAMS Stock Holding History

Deutsche Bank’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.99M	Buy	124,775 +812	+0.7%	+$26.4K	﹤0.01%	1418
2025 Q4	$4.35M	Buy	123,963 +55,538	+81%	+$2.02M	﹤0.01%	1366
2025 Q3	$1.95M	Buy	68,425 +333	+0.5%	+$7.98K	﹤0.01%	1783
2025 Q2	$1.23M	Sell	68,092 -4,305	-6%	-$78.5K	﹤0.01%	1965
2025 Q1	$1.48M	Buy	72,397 +69,749	+2,634%	+$1.55M	﹤0.01%	1945
2024 Q4	$68.1K	Buy	2,648 +199	+8%	+$4.23K	﹤0.01%	3371
2024 Q3	$40.7K	Buy	+2,449	New	+$42.4K	﹤0.01%	3398

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Deutsche Bank's NAMS Position: Q1 2026 in Review

Deutsche Bank increased its NewAmsterdam Pharma (NAMS) stake by 0.66% in Q1 2026, buying an estimated $26.4K and bringing the position to 124,775 shares worth $3.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1418.

Deutsche Bank first reported a position in NAMS in Q3 2024 and has held it in 7 quarters since. The position peaked at $4.35M in Q4 2025. 170 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

Deutsche Bank held 124,775 shares of NewAmsterdam Pharma worth $3.99M as of Q1 2026.
Deutsche Bank bought 812 NewAmsterdam Pharma shares in Q1 2026, an estimated $26.4K.
NewAmsterdam Pharma made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #1418 holding.
Deutsche Bank first reported a position in NewAmsterdam Pharma in Q3 2024 and has held it in 7 quarters since.
Deutsche Bank's NewAmsterdam Pharma position peaked at $4.35M in Q4 2025.
170 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.